Developer docs
API playgroundTry for free, no card

Search company profiles

Quench Bio

Full company profile

uuid0004qhw

Namestring
Quench Bio
Websiteurl
quenchbio.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Quench Bio is a Cambridge, Massachusetts-based biotechnology company founded in 2018 that develops therapeutics targeting gasdermin biology — a pathway governing pyroptotic cell death and inflammatory cytokine release — to treat severe inflammatory diseases. The company's scientific premise is that selective modulation of gasdermin-mediated inflammatory cell death could address indications underserved by conventional anti-inflammatory and immunosuppressive approaches. The company's platform and pipeline details, including specific lead candidates and target indications beyond "severe inflammatory diseases," are not disclosed in the available data.

On the business side, Quench Bio has operated as a private, venture-backed preclinical-stage biotech. The company closed a $50 million Series A in January 2020 led by RA Capital Management with AbbVie, Arix Bioscience, and Atlas Venture participating, after initial formation backing from Arix Bioscience and Atlas Venture in 2018. Quench Bio has never disclosed commercial product revenue, partnership economics, or licensing income; its capital structure is consistent with a research-stage entity financed almost entirely by equity. The firm has no disclosed manufacturing, commercial, or distribution infrastructure and operates with 1-10 employees.

Operating-status signals are negative. The company's primary web domain, quenchbio.com, is listed for sale on HugeDomains at $12,795, and the aggregated data flags operating status as "closed." Combined with the absence of any disclosed follow-on financing, pipeline advancement, partnership, or hiring since the 2020 Series A, this pattern is consistent with a wind-down, dormancy, or asset-sale trajectory rather than active commercial development.

Short descriptiontext

Quench Bio is a Cambridge, Massachusetts-based preclinical biotechnology company founded in 2018 that develops therapeutics targeting gasdermin biology to treat severe inflammatory diseases, backed by RA Capital, AbbVie, Arix, and Atlas.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
inflammatory disease drugs, gasdermin biology therapeutics, biopharmaceutical drug discovery, inflammatory pipeline development, small molecule immunology
Industry2 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Inflammatory Disease Biopharmaceuticals
Social media profiles2 records
Cost components3 values
Personnel, Technology or R&D, Operations
Pricing details1 tier
1Domain purchase - one-time payment
ModelOne time/ perpetual licenseBilling cadenceMonthly
Notes

Buy now for $12,795

hugedomains.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Quench Bio is a developer of gasdermin biology drugs intended for the treatment of severe inflammatory diseases. The company is engaged in biopharmaceutical drug discovery, building a pipeline of therapeutics that target gasdermin-mediated inflammatory pathways.

Differentiator
Functional benefit
Problem solved
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Inflazome
TypeDirect peer
Description

Developed small-molecule NLRP3 inflammasome inhibitors targeting the same pyroptosis/inflammation biology as Quench Bio's gasdermin D programs. Acquired by Roche in 2020, validating pharma demand for this mechanistic class.

TypeDirect peer
Description

IFM Therapeutics' subsidiary developed a small-molecule NLRP3 antagonist (IFM-2427) for inflammatory diseases. Acquired by Novartis in 2019; directly comparable to Quench Bio's inflammasome/pyroptosis thesis.

TypeDirect peer
Description

UK- and US-based biotech developing small-molecule NLRP3 inflammasome inhibitors for inflammatory and neuroinflammatory diseases. Competes with Quench Bio for the same pharma BD and scientific positioning.

TypeDirect peer
Description

Clinical-stage developer of dapansutrile, an oral NLRP3 inhibitor. Addresses overlapping inflammasome-mediated inflammatory disease indications as Quench Bio's gasdermin D program.

TypeEmerging player
Description

Focused on inflammasome pathway inhibition, including IC 100, an inflammasome ASC inhibitor. Operates in adjacent inflammasome biology with similar target rationale to Quench Bio.

TypeEmerging player
Description

Structure-based drug discovery company developing small molecules against innate immune targets, including inflammasome components. Comparable in stage and platform-driven approach to a gasdermin D program.

TypeEmerging player
Description

China-based clinical-stage biotech with disclosed gasdermin D inhibitor programs, directly addressing the same novel target as Quench Bio and representing the closest mechanistic competitor.

TypeBroad incumbent
Description

Acquired IFM Tre and built a leading inflammasome/pyroptosis portfolio. Broad incumbent in immunology with the resources to outcompete small players like Quench Bio on clinical translation and BD.

TypeBroad incumbent
Description

Acquired Inflazome in 2020 to anchor its NLRP3/inflammasome strategy; comparable broad incumbent pursuing the same upstream inflammation biology as Quench Bio.

TypeBroad incumbent
Description

Major immunology incumbent and a direct investor in Quench Bio's 2020 Series A; comparable as both a strategic with overlapping inflammation franchise (Humira/Skyrizi/Rinvoq) and as a counterparty likely to evaluate gasdermin assets.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quench Bio

Inflammatory Disease Biopharmaceuticalsquenchbio.com

Quench Bio is a Cambridge, Massachusetts-based preclinical biotechnology company founded in 2018 that develops therapeutics targeting gasdermin biology to treat severe inflammatory diseases, backed by RA Capital, AbbVie, Arix, and Atlas.

What Quench Bio does

Quench Bio is a Cambridge, Massachusetts-based biotechnology company founded in 2018 that develops therapeutics targeting gasdermin biology — a pathway governing pyroptotic cell death and inflammatory cytokine release — to treat severe inflammatory diseases. The company's scientific premise is that selective modulation of gasdermin-mediated inflammatory cell death could address indications underserved by conventional anti-inflammatory and immunosuppressive approaches. The company's platform and pipeline details, including specific lead candidates and target indications beyond "severe inflammatory diseases," are not disclosed in the available data.

On the business side, Quench Bio has operated as a private, venture-backed preclinical-stage biotech. The company closed a $50 million Series A in January 2020 led by RA Capital Management with AbbVie, Arix Bioscience, and Atlas Venture participating, after initial formation backing from Arix Bioscience and Atlas Venture in 2018. Quench Bio has never disclosed commercial product revenue, partnership economics, or licensing income; its capital structure is consistent with a research-stage entity financed almost entirely by equity. The firm has no disclosed manufacturing, commercial, or distribution infrastructure and operates with 1-10 employees.

Operating-status signals are negative. The company's primary web domain, quenchbio.com, is listed for sale on HugeDomains at $12,795, and the aggregated data flags operating status as "closed." Combined with the absence of any disclosed follow-on financing, pipeline advancement, partnership, or hiring since the 2020 Series A, this pattern is consistent with a wind-down, dormancy, or asset-sale trajectory rather than active commercial development.

Quench Bio firmographics

Firmographics
Name
Quench Bio
Website
https://quenchbio.com
Company type
Private
Founded year
2018
Operating status
Closed
Headcount range
1–10 employees
Short description
Quench Bio is a Cambridge, Massachusetts-based preclinical biotechnology company founded in 2018 that develops therapeutics targeting gasdermin biology to treat severe inflammatory diseases, backed by RA Capital, AbbVie, Arix, and Atlas.
Ownership category
akta.pro rank

Quench Bio industry classification

Industry
Product category
Inflammatory Disease Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Inflammatory disease drugs
  • Gasdermin biology therapeutics
  • Biopharmaceutical drug discovery
  • Inflammatory pipeline development
  • Small molecule immunology

Where Quench Bio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Quench Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMonthlyDomain purchase - one-time payment

Quench Bio product offering

Product offering

Core offering

Quench Bio is a developer of gasdermin biology drugs intended for the treatment of severe inflammatory diseases. The company is engaged in biopharmaceutical drug discovery, building a pipeline of therapeutics that target gasdermin-mediated inflammatory pathways.

Differentiator

Problem solved

Functional benefit

Companies that use Quench Bio

Customer profile

Ideal customer profiles1 record

Quench Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Quench Bio partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights4 records

Quench Bio competitors and assessment

Company assessment

Direct peers

  • Inflazome: Developed small-molecule NLRP3 inflammasome inhibitors targeting the same pyroptosis/inflammation biology as Quench Bio's gasdermin D programs. Acquired by Roche in 2020, validating pharma demand for this mechanistic class.
  • IFM Tre: IFM Therapeutics' subsidiary developed a small-molecule NLRP3 antagonist (IFM-2427) for inflammatory diseases. Acquired by Novartis in 2019; directly comparable to Quench Bio's inflammasome/pyroptosis thesis.
  • NodThera: UK- and US-based biotech developing small-molecule NLRP3 inflammasome inhibitors for inflammatory and neuroinflammatory diseases. Competes with Quench Bio for the same pharma BD and scientific positioning.
  • Olatec Therapeutics: Clinical-stage developer of dapansutrile, an oral NLRP3 inhibitor. Addresses overlapping inflammasome-mediated inflammatory disease indications as Quench Bio's gasdermin D program.

Emerging players

  • ZyVersa Therapeutics: Focused on inflammasome pathway inhibition, including IC 100, an inflammasome ASC inhibitor. Operates in adjacent inflammasome biology with similar target rationale to Quench Bio.
  • Ventus Therapeutics: Structure-based drug discovery company developing small molecules against innate immune targets, including inflammasome components. Comparable in stage and platform-driven approach to a gasdermin D program.
  • GenFleet Therapeutics: China-based clinical-stage biotech with disclosed gasdermin D inhibitor programs, directly addressing the same novel target as Quench Bio and representing the closest mechanistic competitor.

Broad incumbents

  • Novartis: Acquired IFM Tre and built a leading inflammasome/pyroptosis portfolio. Broad incumbent in immunology with the resources to outcompete small players like Quench Bio on clinical translation and BD.
  • Roche: Acquired Inflazome in 2020 to anchor its NLRP3/inflammasome strategy; comparable broad incumbent pursuing the same upstream inflammation biology as Quench Bio.
  • AbbVie: Major immunology incumbent and a direct investor in Quench Bio's 2020 Series A; comparable as both a strategic with overlapping inflammation franchise (Humira/Skyrizi/Rinvoq) and as a counterparty likely to evaluate gasdermin assets.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights3 records

Customer concentration

Quench Bio social profiles

Digital presence

Quench Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quench Bio leadership team

Management profile

Number of profiles

Profiles1 record

Quench Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quench Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quench Bio

What does Quench Bio do?

Quench Bio is a developer of gasdermin biology drugs intended for the treatment of severe inflammatory diseases. The company is engaged in biopharmaceutical drug discovery, building a pipeline of therapeutics that target gasdermin-mediated inflammatory pathways.

Is Quench Bio a public or private company?

Quench Bio is a private company. It is classified as venture growth investor backed and is currently closed.

When was Quench Bio founded?

Quench Bio was founded in 2018. It employs 1 to 10 people.

Where is Quench Bio based?

Quench Bio is headquartered in Cambridge, United States, in the North America region.

Who are Quench Bio's main competitors?

Direct peers on record are Inflazome, IFM Tre, NodThera and Olatec Therapeutics. Emerging players are ZyVersa Therapeutics, Ventus Therapeutics and GenFleet Therapeutics. Broad incumbents are Novartis, Roche and AbbVie.

Does Quench Bio have an API?

No public API is recorded for Quench Bio.

What industry is Quench Bio in?

Quench Bio's product category is Inflammatory Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy). Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LifescivcOde to Scientists - LifeSciVCSamantha Truex, CEO of Quench Bio, praises scientists' pandemic work, noting her team's dedication despite assay failures and CRO errors. She highlights the Broad Institute's 24/7 COVID testing service and the industry's improved Gallup poll ranking. She expresses hope that scientists' efforts will improve industry perceptions.PR NewswireQuench Bio is named one of Fierce Biotech's "Fierce 15" Biotech Companies of 2020Quench Bio, a Cambridge, Massachusetts-based biotechnology company developing medicines for severe inflammatory diseases, was named by Fierce Biotech to its 2020 Fierce 15 list recognizing the most promising private biotech companies. The company leverages new insights into gasdermin biology and innate immunity to develop therapies targeting pore-forming gasdermins. Quench Bio launched in January 2020 with $50 million in funding from investors including Atlas Venture, Arix Bioscience, RA Capital, and AbbVie Ventures.LifescivcLeave a Ladder Down, Part Deux - LifeSciVCQuenchBio CEO Samantha Truex reflects on her career mentors and the importance of leaving a ladder down for others. She argues that mentoring must extend to reaching people at the bottom of the career grid, not just those already aware of it. She challenges readers to help at least one person access life sciences careers this year.FinSMEsQuench Bio Raises $50M in Series A FinancingQuench Bio, a Cambridge-based biotech developing medicines for severe inflammatory diseases, completed a $50M Series A financing led by RA Capital Management. The round included participation from AbbVie Ventures, Atlas Venture, and Arix Bioscience, and added Josh Resnick to the board.PR NewswireQuench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory DiseasesQuench Bio announced the closing of a $50 million Series A financing round led by RA Capital Management, with participation from AbbVie Ventures, Atlas Venture, and Arix Bioscience. The funding will support the development of first-in-class medicines targeting gasdermin to treat severe inflammatory diseases such as rheumatoid arthritis and lupus. This investment enables the company to advance its lead therapeutic approach which aims to inhibit multiple inflammatory cell death pathways.PR NewswireArix Co-founds Quench Bio With Series A FinancingArix Bioscience plc co-founded biotech company Quench Bio, which emerged from stealth mode with the completion of a $50 million Series A financing led by RA Capital, with participation from AbbVie Ventures, Atlas Venture, and Arix itself. Quench Bio is developing medicines targeting the Gasdermin D protein to treat severe inflammatory diseases by inhibiting key inflammatory cell death pathways including pyroptosis and NETosis. The company is led by CEO Samantha Truex, former Chief Business Officer of Padlock Therapeutics, and represents a transatlantic collaboration combining European science from Germany's Max Planck Society with US biotech expertise.VC News DailyQuench Bio Closes $50M Series A FinancingQuench Bio has completed a $50 million Series A financing round, led by RA Capital Management, with the participation of Abbvie Ventures, Atlas Venture, and Arix Bioscience. The funding will support Quench Bio's development of medicines targeting Gasdermin D, a critical protein involved in inflammatory disease pathways. The company aims to address significant unmet medical needs in severe inflammatory diseases through innovative drug discovery techniques.